IP Library Granted Patent US 9,795,620
Granted Patent B2
US 9,795,620 · App. 15/374,951 · Granted Oct 24, 2017

Oral composition of celecoxib for treatment of pain

Inventors: Ankit Baheti (Indore, IN); Bijay Kumar Padhi (Buguda, IN); Supritha Vakada (Hyderabad, IN); Rajeev Singh Raghuvanshi (Gurgaon, IN)
Assignee: Dr. Reddy's Laboratories, Ltd.
A61K31/635A61K9/0053A61K9/0095A61K9/08A61K47/10A61K47/14A61K47/26A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,795,620
App. No.
15/374,951
Granted
Oct 24, 2017
Kind
B2
Abstract

The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.

Claims (58)

1. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 20% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

2. The method of claim 1 , wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:

AUC (0-15 min) from about 10 ng·h/mL to about 80 ng·h/mL;

AUC (0-30 min) from about 80 ng·h/mL to about 400 ng·h/mL;

AUC (0-1 hr) from about 400 ng·h/mL to about 1500 ng·h/mL;

AUC (0-2 hr) from about 1000 ng·h/mL to about 4000 ng·h/mL;

AUC (0-t) at least about 2000 ng·h/mL;

AUC (0-∞) of at least about 2000 ng·h/mL; and

T lag of not more than 8 minutes.

3. The method of claim 1 , wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

4. The method claim 1 , wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

5. The method of claim 1 , wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

6. The method of claim 5 , wherein said composition has a pH of from about 3 to about 7.

7. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 40% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

8. The method of claim 7 , wherein said reduced dose of celecoxib is about 240 mg.

9. The method of claim 7 , wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:

AUC (0-15 min) from about 10 ng·h/mL to about 80 ng·h/mL;

AUC (0-30 min) from about 80 ng·h/mL to about 400 ng·h/mL;

AUC (0-1 hr) from about 400 ng·h/mL to about 1500 ng·h/mL;

AUC (0-2 hr) from about 1000 ng·h/mL to about 4000 ng·h/mL;

AUC (0-t) at least about 2000 ng·h/mL;

AUC (0-∞) of at least about 2000 ng·h/mL; and

T lag of not more than 8 minutes.

10. The method claim 7 , wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

11. The method of claim 10 , wherein said pain is associated with migraine.

12. The method claim 7 , wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

13. The method of claim 7 , wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

14. The method of claim 13 , wherein said composition has a pH of from about 3 to about 7.

15. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 55% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

16. The method claim 15 , wherein said reduced dose of celecoxib is about 180 mg.

17. The method of claim 15 , wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:

AUC (0-15 min) from about 10 ng·h/mL to about 80 ng·h/mL;

AUC (0-30 min) from about 80 ng·h/mL to about 400 ng·h/mL;

AUC (0-1 hr) from about 400 ng·h/mL to about 1500 ng·h/mL;

AUC (0-2 hr) from about 1000 ng·h/mL to about 4000 ng·h/mL;

AUC (0-t) at least about 2000 ng·h/mL;

AUC (0-∞) of at least about 2000 ng·h/mL; and

T lag of not more than 8 minutes.

18. The method of claim 15 , wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

19. The method of claim 18 , wherein said pain is associated with migraine.

20. The method claim 15 , wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

21. The method of treating pain of claim 15 , wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

22. The method of treating pain of claim 21 , wherein said composition has a pH of from about 3 to about 7.

23. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 70% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

24. The method of claim 23 , wherein said reduced dose of celecoxib is about 120 mg.

25. The method claim 23 , wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:

AUC (0-15 min) from about 10 ng·h/mL to about 80 ng·h/mL;

AUC (0-30 min) from about 80 ng·h/mL to about 400 ng·h/mL;

AUC (0-1 hr) from about 400 ng·h/mL to about 1500 ng·h/mL;

AUC (0-2 hr) from about 1000 ng·h/mL to about 4000 ng·h/mL;

AUC (0-t) at least about 2000 ng·h/mL;

AUC (0-∞) of at least about 2000 ng·h/mL; and

T lag of not more than 8 minutes.

26. The method of claim 23 , wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

27. The method of claim 26 , wherein said pain is associated with migraine.

28. The method of claim 23 , wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

29. The method of treating pain of claim 23 wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

30. The method of treating pain of claim 29 , wherein said composition has a pH of from about 3 to about 7.

Assignments (5)
SECURITY INTEREST Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY; SCILEX PHARMACEUTICALS INC.; SEMNUR PHARMACEUTICALS, INC.
To: ACQUIOM AGENCY SERVICES LLC, AS AGENT
Reel/Frame 064987/0939 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2023
From: BIODELIVERY SCIENCES INTERNATIONAL, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 063388/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2023
From: DR. REDDY'S LABORATORIES LTD.
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 062504/0230 →
RELEASE OF SECURITY INTEREST Recorded Mar 22, 2022
From: BPCR LIMITED PARTNERSHIP
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 059344/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2017
From: BAHETI, ANKIT; PADHI, BIJAY KUMAR; VAKADA, SUPRITHA; RAGHUVANSHI, RAJEEV SINGH
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 041219/0569 →
Priority Claims (2)
IN 2682/CHE/2015 · May 28, 2015 · national
IN 6614/CHE/2015 · Dec 10, 2015 · national
Continuity (2)
Continuation 15167922 · May 27, 2016
Related Publication 20170119798A1 · May 4, 2017